Stockwinners Market Radar for February 14, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST Cathie Wood's ARK Investment bought 74K shares of Iridium today

19:50 EST FDA grants Mesoblast orphan-drug designation for Revascor - Mesoblast Limited "announced that the United States Food and Drug Administration has granted its allogeneic cell therapy Revascor, or rexlemestrocel-L, an Orphan-Drug Designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome, a potentially life threatening congenital heart condition. This follows the Rare Pediatric Disease Designation granted by FDA last month. Results from a blinded, randomized, placebo-controlled prospective trial of REVASCOR conducted in the United States in children with HLHS were published in the December 2023 issue of the peer reviewed The Journal of Thoracic and Cardiovascular Surgery Open. In the HLHS trial conducted in 19 children, a single intramyocardial administration of REVASCOR at the time of staged surgery resulted in the desired outcome of significantly larger increases in left ventricular end-systolic and end-diastolic volumes over 12 months compared with controls as measured by 3D echocardiography. These changes are indicative of clinically important growth of the small left ventricle, facilitating the ability to have a successful surgical correction, known as full biventricular, BiV, conversion, which allows for a normal two ventricle circulation with the surgically repaired left ventricle taking over circulatory support to the body. Without full BiV conversion the right heart chamber is under excessive strain with increased risk of heart failure and death."

19:24 EST NorthWestern Energy raises quarterly dividend 1.6% to 65c per share - NorthWestern Energy Group's Board of Directors declared a quarterly common dividend of $0.65 per share (a 1.6% increase over the prior quarter's dividend) payable March 29, 2024 to common shareholders of record as of March 15, 2024. Over the longer-term, we expect to maintain a dividend payout ratio within a targeted 60-70% range.

18:36 EST Patterson-UTI sees FY24 CapEx roughly $740M - The company said, "For the first quarter, Other revenue and adjusted gross profit is expected to be roughly flat with the fourth quarter. For the first quarter, we expect selling, general and administrative expense of approximately $65 million, and depreciation, depletion, amortization, and impairment expense of approximately $280 million. For 2024, we expect an effective tax rate of approximately 24%, with annual cash taxes expected to be $35-45 million after utilizing tax attributes to offset a portion of our taxable income. For 2024, we expect capital expenditures of approximately $740 million, comprised of $285 million for Drilling Services, $360 million for Completion Services, $55 million for Drilling Products, and $40 million for Other and Corporate. For purposes of the shareholder return target, the Company defines free cash flow as net cash provided by operating activities less capital expenditures. The shareholder return target, including the amount and timing of any dividend payments and/or share repurchases are subject to the discretion of the Company's Board of Directors and will depend upon business conditions, results of operations, financial condition, terms of the Company's debt agreements and other factors."

18:23 EST Generac CEO: Secular growth opportunities in our markets are intact - In an interview on CNBC's Mad Money, Aaron Jagdfeld said Q4 was a turning point for Generac. He expects to get back to growing the residential business. The company is twice the size that it was pre-pandemic, he noted.

18:00 EST Ionis Pharmaceuticals' olezarsen granted FDA orphan designation - According to a post on the FDA's website, Ionis Pharmaceuticals' olezarsen was granted orphan designation. Reference Link

17:48 EST Ampio reports results from OA-201 studies do not support IND submission - Ampio announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity. Ampio reported that the efficacy results of these studies do not support an Investigational New Drug, or IND, submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce pain and preserve cartilage in nonclinical models of osteoarthritis of the knee, the pain reduction benefit was not observed in the data from the recent set of preclinical studies which utilized a larger population of animal subjects. "We believe we need to demonstrate a statistically significant improvement in both pain reduction and cartilage protection to support the IND and justify the capital necessary to complete the planned Phase 1/2 trial. The data from the larger nonclinical pain reduction trial simply do not support the same pain reduction benefit as was demonstrated in the earlier, smaller, proof-of-concept trials," said Michael Martino, Ampio's Chief Executive Officer. The company's management and the board are currently assessing both internal and external options. The company will be taking immediate actions to preserve its cash in order to be able to adequately fund any option identified by the board.

17:38 EST Soros buys Birkenstock and Merck, exits LPL Financial and General Motors - George Soros' Soros Fund Management disclosed in an SEC filing its holdings as of December 31, 2023. Soros' new buys during the fourth quarter included, by size of position, Birkenstock (BIRK), Merck (MRK), Eli Lilly (LLY), and Avantor (AVTR). Soros' exited positions during the quarter included, by size of previous position, LPL Financial (LPLA), General Motors (GM), Vail Resorts (MTN), and Five9 (FIVN). Soros increased its stake in holdings, including by size of previous position, Splunk (SPLK), AerCap (AER), Sempra (SRE), and Novo (NVO). Soros reduced its stake in holdings, including by size of previous position, Aptiv (APTV), Intuit (INTU), Alphabet (GOOGL), Kenvue (KVUE), and Amazon (AMZN). Soros' top holdings as of December 31, in order of size, were Splunk, AerCap, Alphabet, and Novo.

17:31 EST Algoma Steel resumes normal steel production - Algoma Steel Group advised that the repair and restart of its blast furnace is complete and steel production resumed on Sunday, February 11. Algoma has strengthened its operations while advancing essential repair work required after a structure supporting utilities piping at Algoma's coke-making plant collapsed on January 20. Algoma remains focused on completing necessary utilities corridor repairs safely and efficiently while increasing coke-making capacity and rebuilding inventory levels. The company will continue to assess supplementing its coke supplies with market purchases to balance its requirement for iron production.

17:16 EST HF Sinclair increases regular cash dividend 11%to 50c per share - HF Sinclair declared a regular quarterly dividend of 50c per share, an increase of 5c from the previous dividend of 45c per share. This dividend represents an 11% increase from the prior quarter and will be paid on March 5 to holders of record of common stock on February 26.

17:07 EST Manulife Financial raises quarterly dividend by 9.6% to 40c per share - The dividend is payable on and after March 19, 2024, to shareholders of record at the close of business on February 28, 2024.

16:59 EST Icahn takes stake in American Electric Power, exits position in Crown Holdings - Carl Icahn's Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2023. Icahn's one new buy during the fourth quarter was American Electric Power (AEP). Icahn exited one position during the quarter, Crown Holdings (CCK). Icahn increased its stake in one holding, Icahn Enterprises (IEP). Icahn reduced its stake in one holding, FirstEnergy (FE). Icahn's top holdings as of December 31, in order of size, were Icahn Enterprises, CVR Energy (CVI), Southwest Gas (SWX), Bausch Health (BHC), and FirstEnergy.

16:51 EST Nelson Peltz's Trian buys GE, cuts Allstate in Q4 - Nelson Peltz's Trian Fund Management disclosed in an SEC Filing its holdings as of December 31, 2023. The fund's two new buys during the fourth quarter included, by size of position, GE (GE) and GE Healthcare (GEHC). Trian reduced its stake in four positions, including by size of previous position Ferguson (FERG), Wendy's (WEN), Allstate (ALL), and Disney (DIS). The fund's top holdings as of December 31, in order of size, were Disney, Janus Henderson (JHG), Ferguson, Wendy's, and Invesco (IVZ).

16:49 EST Starboard takes new stakes in Fortrea, News Corp - Jeffrey Smith's Starboard Value disclosed in an SEC filing its holdings as of December 31, 2023. Starboard's three new buys during the fourth quarter included, by size of position, Fortrea (FTRE), News Corp Class B (NWS), and News Corp Class A (NWSA). Starboard increased its stake in five holdings, including by size of previous position, Algonquin Power (AQN), Humana (HUM), and Bloomin' Brands (BLMN). Starboard reduced its stake in five holdings, including by size of previous position, Aecom (ACM), Vertiv (VRT), Rogers (RCI), Mercury Systems (MRCY), and Salesforce (CRM). Starboard's top holdings as of December 31, in order of size, were GoDaddy (GDDY), Humana, Gen Digital (GEN), Wix.com (WIX), and Salesforce.

16:47 EST Lone Pine buys GE, exits Tempur Sealy in Q4 - Stephen Mandel's Lone Pine disclosed in an SEC filing its holdings as of December 31, 2023. The fund's four new buys during the fourth quarter included, by size of position, Intuit (INTU), Blackstone (BX), Philip Morris (PM), and GE (GE). Lone Pine exited a number of shares during the period, including by size of previous position Alphabet Class A (GOOGL), TransDigm (TDG), BILL Holdings (BILL), Tempur Sealy (TPX), and Floor & Decor (FND). The fund increased its position in Block (SQ), Meta (META), Bath & Body Works (BBWI), Dick's Sporting (DKS), and ASML (ASML), and reduced its stake in Mastercard (MA), Workday (WDAY), Epam Systems (EPAM), Live Nation (LYV), and TSMC (TSM). Lone Pine's top holdings as of December 31, in order of size, were Meta, Amazon (AMZN), TSMC, Microsoft (MSFT), and Salesforce (CRM).

16:43 EST Greenlight buys Alight, exits Southwestern in Q4 - David Einhorn's Greenlight Capital disclosed in an SEC filing its holdings as of December 31, 2023. The fund's new buys for the fourth quarter included, by size of position, Alight (ALIT), Viatris (VTRS), AerCap (AER), SPDR S&P Aerospace & Defense ETF (XAR), and Invesco Aerospace & Defense ETF (PPA). Greenlight exited four positions during the quarter, including by size of previous position Southwestern Energy (SWN), iShares Silver Trust (SLV), Resideo (REZI), and Advance Auto Parts (AAP). The fund increased its stake in a number of holidngs, including by size of previous position Kyndryl (KD), Tenet (THC), ODP Corp. (ODP), Graphic Packaging (GPK), and DHT Holdings (DHT). Greenlight reduced its stake in four holdings, namely Consol Energy (CEIX), SPDR Gold Shares (GLD), Brighthouse Financial (BHF), and Green Brick (GRBK). The fund's top holdings as of December 31, in order of size, were Green Brick, Consol, Brighthouse, Kyndryl, and Tenet.

16:39 EST Nu Skin sinks 20% to $14 after dividend cut, guidance miss

16:38 EST Berkshire Hathaway boosts Chevron position, cuts HP and Apple stakes - Warren Buffett's Berkshire Hathaway disclosed in an SEC filing its holdings as of December 31, 2023. Berkshire exited four positions during the fourth quarter, including by size of previous position, DR Horton (DHI), Markel Group (MKL), StoneCo (STNE), and Globe Life (GL). Berkshire increased its stake in three holdings, including by size of previous position, Chevron (CVX), SiriusXM (SIRI), and Occidental (OXY), . Berkshire reduced its stake in three holdings, including by size of previous position, HP (HPQ), Paramount Global (PARA), and Apple (AAPL). Berkshire's top holdings as of December 31, in order of size, were Apple, Bank of America (BAC), American Express (AXP), Coca-Cola (KO), and Chevron.

16:36 EST Aterian announces fixed cost reduction plan amid SKU rationalization program - Aterian announced a fixed cost reduction as part of the final steps of its previously announced SKU rationalization program. The Company also released certain preliminary fourth quarter 2023 results. Fixed Cost Reduction Plan The fixed cost reduction plan is expected to align the Company's costs to what the Company believes will be the appropriate level as it drives towards adjusted EBITDA profitability in the second half of 2024. The Company expects to reduce its workforce by 21 employees and 27 contractors, primarily in the Philippines and Poland, and to recognize annualized savings of approximately $4M. The Company expects to primarily complete the plan by the end of the first quarter 2024 and to recognize and pay restructuring charges, primarily related to severance, of 900,000K in such quarter. "Today's announcement reflects a continuation of earlier initiatives to focus, simplify and stabilize our core business and to reposition Aterian for profitability and growth. Arty and I are proud of our team's efforts, and we expect further progress in the quarters to come. To our impacted colleagues, the decisions made were difficult, and Arty and I are deeply grateful for your contributions to Aterian. We wish each of you all the best," said Joe Risico, Aterian's Co-CEO. As part of this plan, the Company has shifted the architecture of its technology platform, AIMEE, away from a fully internally developed model to an integrated third-party, best-of-breed model. This shift is expected to account for approximately $0.7 million of the expected annualized savings announced today. "This shift to a best-of-breed integrated third-party approach, is not only expected to lead to cost-savings but is also expected to increase our speed and agility to support our push to an omnichannel strategy and address our continually changing marketplace environment," said Arturo Rodriguez, Aterian's Co-CEO and CFO; and he added "our technology will continue to be lead by our CTO, Roi Zahut, and we continue to believe being tech-enabled is the key to our future. Together, these changes have increased our optimism regarding our path to adjusted EBITDA profitability in the second half of 2024."

16:34 EST Radian Group raises quarterly dividend 9% to 24.5c per share - The dividend is payable on March 12, 2024, to stockholders of record as of February 26, 2024.

16:32 EST Udemy announces $100M share repurchase program - Udemy announced its board of directors approved a share repurchase program, authorizing the purchase of up to $100M of the company's common stock, effective immediately.

16:32 EST SuRo Capital to commence tender to repurchase up to 2M shares - SuRo Capital announced that it will commence a modified "Dutch Auction" tender offer to purchase up to 2M shares of its common stock at a price per share not less than $4.00 and not greater than $5.00 in $0.10 increments, using available cash. "As we have consistently demonstrated, SuRo Capital is committed to initiatives that enhance shareholder value, and we believe the market is currently undervaluing our portfolio. Accordingly, on February 14, 2024, our Board of Directors authorized a modified Dutch Auction Tender Offer to purchase up to 2 million shares of our common stock at a price per share between $4.00 and $5.00. Given our stock is trading at a significant discount to net asset value, we believe the modified Dutch Auction Tender offer to be an efficient and accretive deployment of capital," said Mark Klein, Chairman and Chief Executive Officer of SuRo Capital.

16:28 EST Cisco to cut 5% of global workforce in restructuring - In a regulatory filing, Cisco announced a restructuring plan in order to "realign the organization and enable further investment in key priority areas." This restructuring plan will impact approximately 5% of Cisco's global workforce. Cisco currently estimates that it will recognize pre-tax charges to its GAAP financial results of approximately $800M, consisting of severance and other one-time termination benefits and other costs. These charges are primarily cash-based. Cisco expects to take the majority of these actions in the third quarter of fiscal 2024 and recognize approximately $500M of these charges. Cisco expects approximately $150M of these charges to be recognized in the fourth quarter of fiscal 2024, and the remaining amount of these charges primarily through the first half of fiscal 2025. Reference Link

16:23 EST Occidental Petroleum sees Q1 total production 1,155-1,195 Mboed

16:23 EST Warrior Met Coal sees FY24 coal sales 7.4M-8.2M tons - Sees FY24 coal production 7.4M-8.0M tons

16:22 EST Cisco falls 5% to $47.90 after lowering FY24 guidance - The company's Q3 guidance also came in below analysts' expectations.

16:20 EST QuantumScape names Siva Sivaram CEO - QuantumScape announced the appointment of current President, Dr. Siva Sivaram, as CEO and as a member of the board of directors, effective February 15, 2024. Co-founder and CEO Jagdeep Singh will continue to serve as Chairman of the Board of Directors. Dr. Sivaram, a semiconductor and data storage industry veteran, joined QuantumScape as President in September 2023. He joined from Western Digital Corp., where he also served as President, leading corporate strategy and technology. His deep technical acumen and decades of experience taking complex emerging technologies into high-volume production, building factories, establishing partnerships and scaling manufacturing worldwide made him a natural fit for the role.

16:19 EST Bristol Myers urges shareholders to reject 'mini-tender' offer by Tutanota - Bristol Myers Squibb announced that it recently became aware of an unsolicited "mini-tender" offer by Tutanota LLC to purchase up to five hundred thousand shares of Bristol Myers Squibb's common stock, representing significantly less than one percent of Bristol Myers Squibb's common stock outstanding, at an offer price of $55 per share. The offer is conditioned on, among other things, the closing price per share of Bristol Myers Squibb's common stock exceeding the Offer Price on the last trading day before the offer expires. Tutanota also states in its offer documents that it expects to extend the offer for successive periods of 45 to 180 days until the market price of Bristol Myers Squibb's common stock exceeds the Offer Price. This means that Bristol Myers Squibb stockholders who tender their shares in the offer will receive a below-market price if the offer conditions are satisfied and their shares are accepted in the tender offer. There is no guarantee that the conditions of the offer will be satisfied. In addition, Bristol Myers Squibb cautions stockholders that if Tutanota extends its offer, payment would be delayed beyond the scheduled expiration date of Friday, February 23, 2024. Bristol Myers Squibb recommends that stockholders do not tender their shares in response to Tutanota's offer because the offer is conditional on the Offer Price being below the market price for Bristol Myers Squibb's common stock and subject to numerous additional conditions, including Tutanota obtaining financing for the offer. Stockholders who have already tendered their shares may withdraw them at any time prior to 5:00 p.m., Eastern Time, on Friday, February 23, 2024, in accordance with the offering documents. Bristol Myers Squibb recommends that stockholders who have not responded to Tutanota's offer take no action.

16:17 EST Merchants Bancorp increases quarterly common dividend 13% to 9c - Merchants Bancorp declared increased its Q1 quarterly cash dividend payable to shareholders of record on March 15 on April 1 to 9c per share on the company's outstanding shares of its common stock.

16:15 EST Twilio says Segment business review to be completed in March - The company said, "Twilio announced that management is undergoing an operational review of the Segment business unit in order to identify the appropriate path forward for improved execution and profitable growth. Twilio management will provide more details on the outcome of this review upon its completion in March of 2024. During the fourth quarter, Twilio recorded a $285.7 million impairment related to the intangible assets acquired as part of the Segment acquisition."

16:14 EST Wag! Group reports Q4 platform participants up 38% from last year - The company "achieved 600,000 Platform Participants in Q4 2023, an increase of 38% from 434,000 in Q4 2022."

16:09 EST Ascent Industries names J. Bryan Kitchen CEO - Ascent Industries announced the promotion of Ascent Chemicals' President J. Bryan Kitchen to Ascent's CEO and Ascent Chemicals' Vice President of Financial Planning and Analysis Ryan Kavalauskas to Ascent's CFO. Mr. Kitchen succeeds President and CEO Chris Hutter, who will remain on the Company's board of directors. Mr. Kavalauskas succeeds CFO Bill Steckel, who will be leaving the Company to pursue other opportunities. "As we continue to make progress towards our long-term strategic goals for Ascent, I'm pleased to announce the promotions of Bryan and Ryan to lead the Company," said Ascent's Executive Chairman Ben Rosenzweig. "Since taking the helm of Ascent Chemicals last year, Bryan has made notable progress improving the operational performance of the business, with Ryan recently playing an integral role leading all financial planning and analysis across the organization. We are excited by the opportunities to continue profitably scaling our specialty chemicals business, and we are eager to have two proven industry leaders drive our Company forward.

16:07 EST Royal Gold sees Q1 stream segment sales 47K-52K GEOs - The company said, "We expect stream segment sales of 47,000 to 52,000 GEOs for the quarter ended March 31, 2024, and we expect to issue guidance for 2024 sales, depreciation, depletion and amortization expense, and effective tax rate early in the second quarter of 2024."

16:03 EST CSX announces 9% boost to dividend to 12c per share - CSX announced that the Company's Board of Directors approved a nine percent increase in its quarterly dividend, 11c to 12c per share. The new 12c quarterly dividend is payable on March 15 to shareholders of record at the close of business on February 29.

16:01 EST Sutter Rock Capital trading halted, news pending

15:09 EST NVR announces $750M share repurchase plan - NVR announced that its Board of Directors has authorized the repurchase of up to an aggregate of $750M of its outstanding common stock. The repurchase authorization does not have an expiration date.

14:15 EST Enersys trading resumes

14:07 EST EnerSys selects Greenville, South Carolina for lithium-ion cell gigafactory - EnerSys has announced that it has selected Greenville, South Carolina to develop a lithium-ion cell gigafactory to advance battery production in the United States. "This new factory represents a long-term opportunity that will enable growth and allow EnerSys to optimize cell sizing in battery solutions for its customers, providing independence from non-domestic cell suppliers. EnerSys has applied for a comprehensive incentive package through South Carolina and Greenville County valued at approximately $200M, which includes a combination of short-term and long-term incentives. The Company intends to use a portion of these proceeds, along with the Inflation Reduction Act IRC 45X tax benefits and potential additional federal funding, to make a $500M investment with the potential to create 500 high-quality new jobs. EnerSys is evaluating the development of a 500,000 square foot state-of the-art manufacturing facility on approximately 140 acres in the Augusta Grove business park in Greenville. The operation, which would be the company's second in South Carolina, would manufacture various form factors of lithium-ion cells for commercial, industrial and defense applications, with a production capacity of four gigawatt hours, or GWh, per year. The company is targeting construction to begin in early 2025 and operations to be online in late 2027," the company stated. The transaction, among other things, is subject to customary closing conditions, final Board approval, regulatory and incentive approvals. "We recognize Greenville as an emerging hub for high-tech companies with an attractive talent pool in a thriving community. EnerSys is accelerating the global clean energy transition by significantly expanding our production of lithium-ion batteries across a broad range of end markets and applications. With the support of South Carolina and Greenville County this factory will help us meet our customers' needs, including those with specific manufacturing requirements for domestic sourced batteries," said EnerSys President and CEO David Shaffer.

13:51 EST Telomir Pharmaceuticals Inc trading halted, volatility trading pause

13:14 EST Colorado AG files lawsuit to block proposed Kroger-Albertsons merger - After a yearlong investigation, Colorado Attorney General Phil Weiser filed a lawsuit in Denver District Court to block the $24.6B proposed merger between Kroger (KR) and Albertsons (ACI). Kroger operates 148 King Soopers and City Market stores and Albertsons operates 105 Safeway and Albertsons stores in the state. According to the lawsuit, the merger would eliminate head-to-head competition between Kroger and Albertsons and consolidate an already heavily concentrated market, which is bad for Colorado shoppers, workers, and suppliers. The lawsuit also challenges an illegal "no-poach" agreement between the two companies during a 2022 strike when employee movement was a threat to Kroger's operations, the AG said. In an attempt to lessen the anticompetitive impacts of the merger, Kroger has presented a proposal to sell off 413 stores and other assets nationwide to C&S Wholesale Grocers. The AG believes the proposal is inadequate because it would not alleviate the anticompetitive effects of the merger, echoing many of the problems that have plagued failed grocery divestitures in the past. Weiser asserts that the Kroger divestiture plan must be viewed with heavy skepticism in light of Albertsons' involvement in a failed divestiture plan when it merged with Safeway in 2015. The lawsuit also seeks $1M in civil penalties from Kroger and Albertsons each for entering into the illegal no-poach and non-solicitation agreement during the 2022 King Soopers strike, and to bar the companies from enforcing or entering into such agreements.

13:02 EST Real Brokerage reports surpassing 15,000 agents - The Real Brokerage announced that it has surpassed 15,000 agents, a "milestone which follows a record-breaking wave of new agent growth in January." In January more than 1,000 real estate professionals joined the company, a marked increase from the previous year, the company stated. "We launched Real with a vision to partner with agents to simplify one of life's most complicated transactions. The programs we've developed and the platform we built provide significant value to this community, and what we offer is resonating with agents throughout the U.S. and Canada. Our rapid growth is a testament to our vision of doing what's right for both agents and the clients they serve," said Real Chairman and CEO Tamir Poleg.

12:50 EST Sherwin-Williams raises dividend 18.2% to 71.5c per share - The board of directors of Sherwin-Williams announced a regular quarterly dividend of 71.5c per common share, an increase of 18.2% over the 60.5c paid in the same quarter in 2023, payable on March 8 to shareholders of record on February 26.

12:15 EST Bakkt Holdings trading halted, news pending

12:00 EST Chemours falls -11.8% - Chemours is down -11.8%, or -$3.60 to $26.89.

12:00 EST Allison Transmission rises 12.4% - Allison Transmission is up 12.4%, or $7.62 to $69.16.

12:00 EST Resideo rises 19.0% - Resideo is up 19.0%, or $3.24 to $20.32.

11:19 EST Trian sends letter to Disney shareholders 'starved of returns' - The Trian Group, which beneficially owns $3.5B of common stock in The Walt Disney Company, released a letter to its fellow Disney shareholders. The letter says in part: "Disney has lost money for its shareholders over a long period of time. A year ago, faced with a proxy contest that sought to bring accountability for these failures, Disney attempted to assure shareholders that a 'significant transformation' was underway. In early 2023, Disney outlined a plan to 'succeed at succession,' reignite the Company's creative engine and achieve profitability in the streaming business. A year later, however, Disney shareholders are no better off. It turns out, Disney's story was just a fairy tale. Disney's stock price is lower now than a year ago; its streaming business lost another $1.7 billion; 2024 earnings per share estimates are down nearly 20%; two of Disney's last five movies have failed to turn a profit; and the Board has still not identified a successor for Mr. Iger. With the stock waning and Disney facing another proxy contest, Disney appears to again be trying to distract shareholders with what we see as a fanciful tale, claiming it has "turned the corner and entered a new era." And with that, Disney announced a slew of new promises and ideas - most still in the process of being developed - hoping that shareholders would just believe all was well and improving. To improve the focus, alignment and accountability of the Board, Disney needs new independent directors. Help us elect Nelson Peltz and Jay Rasulo, who pledge to ask hard questions, work with the rest of the Board and management to develop thoughtful strategies, align the interests of executives with shareholders and hold the leadership team accountable for performance. And to do so all the time, not just when the company faces a proxy contest. To ensure the election of Nelson Peltz and Jay Rasulo, it is essential that shareholders vote "FOR" Trian Nominees, Nelson Peltz and Jay Rasulo, and "WITHHOLD" on Disney Nominees, Michael B.G. Froman and Maria Elena Lagomasino, and All Three Blackwells Nominees."

11:17 EST MicroCloud Hologram Inc trading resumes

11:08 EST Disney has 'one of the best, if not the best' amalgamation of brands, Peltz says

11:05 EST Trian's Peltz sees 'very little meat on the bones' of Disney announcements - Peltz says regarding Disney's increased dividend and increased buyback that "as a shareholder I love it, but can we really afford it?" Trian's Nelson Peltz is being interviewed on CNBC regarding his position in Disney and ongoing proxy fight for representation on the company's board.

10:46 EST Numinus congratulates Lykos on FDA acceptance of NDA for MDMA-assisted therapy - Numinus Wellness congratulates the Multidisciplinary Association for Psychedelic Studies or incubating the research that led to the first new drug application to the USFDA, submitted by Lykos Therapeutics on the acceptance of its new drug application to the U.S. Food and Drug Administration or MDMA used in combination with psychological intervention for individuals with PTSD. The FDA has granted the application a priority review, which mandates the authority to take action within six months. A Prescription Drug User Fee Act target action date of August 11, 2024, has been set. "This is an exciting development and, if approved, would be the first MDMA-assisted therapy available in the U.S. for the millions of Americans struggling with PTSD," said Payton Nyquvest, Numinus Founder and CEO. "Getting here was the result of over 20 years of clinical research that was begun by MAPS, the nonprofit organization that founded Lykos, and we are proud to have collaborated with them through participation in the clinical research at our Cedar Clinical Research facilities. There needs to be a dedicated focus on building the infrastructure to be able to administer MDMA-AT if the FDA approves. Numinus has been at the forefront of this effort through training and offering services that are sustainable and scalable while ensuring the highest quality outcomes for clients. We look forward to actively supporting these efforts in the immediate future to continue to help meet the needs of over the 14 million people diagnosed with PTSD in the United States."

10:26 EST Iqvia shares up 10% to $236.09 after Q4 earnings beat estimates

10:10 EST QFTA Inc trading resumes

10:07 EST Renovaro BioSciences responds to Hindenburg's 'baseless attacks' - The following is a statement by Renovaro in response to Hindenburg's recent opinion piece: "We felt compelled to comment on the shorter Hindenburg's opinion piece. The one thing Hindenburg got right is that the Board of the Company has remained steadfast in their confidence and support in the lifesaving potential of Renovaro. In fact, four exceptional leaders in the field of technology and business have recently joined the Board. The rest of the diatribe is largely rehashed material they have been using in a transparent attempt to make money as an active shorter of the Company's stock - a fact that is buried at the very end of the opinion piece: 'You should assume that as of the publication date of any short-biased report or letter, Hindenburg Research along with our clients and/or investors has a short position in all stocks covered herein, and therefore stands to realize significant gains in the event that the price of any stock covered herein declines.' In addition to Hindenburg's shorter attack, we became aware yesterday that our Company was listed without our knowledge on the Berlin stock exchange. We are taking immediate legal action to file a complaint with the proper authorities. The commentary itself is riddled with falsehoods and misleading statements. Indeed, there is a heavy caveat - again, buried at the end - that what is stated is mere opinion without claims of accuracy: 'information is presented 'as is,' without warranty of any kind - whether express or implied. Hindenburg Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information.... All expressions of opinion are subject to change without notice, and Hindenburg Research does not undertake to update or supplement this report.' In an apparent desire to make profit at the expense of other Renovaro shareholders and, potentially, the lives of patients, there is a new false claim about the innovative and advanced AI capabilities of GEDiCube, now RenovaroCube." "I have been in the technology business for nearly four decades, including leading multiple acquisitions," said Avram Miller, Co-Founder of Intel Capital, "After spending many hours and days learning in depth about the power of the deep machine learning of RenovaroCube, I am convinced it is among the most advanced and creative technologies, and is led by a very talented team. While it is initially being applied to the accelerated development of next generation health care products, I believe the depth of the insights could very well expand to become the backbone for a number of large commercial markets. In addition, today's announcement of a binding LOI with Cyclomics positions the combination of cutting-edge technologies to be at the forefront of liquid biopsies for cancer and other diseases. I believe we are building a first-class company based in strong technology and science with an impressive commercially-based organization. I am very excited to be part of this journey."

10:06 EST Lockheed Martin CFO says attrition fell below 5% companywide in 2023

10:05 EST Lockheed Martin CFO: Supply chain on-time deliveries improved in January - CFO Jay Malave is speaking at the TD Cowen 45th Annual Aerospace & Defense Conference.

10:04 EST Syntec Optics completes $5.3M in orders, adds $2.4M in further orders - Syntec Optics scaled its production of ultra-high precision satellite optics with $5.3 million in orders and then further added $2.4 million in current orders.

10:00 EST DaVita rises 9.5% - DaVita is up 9.5%, or $10.85 to $124.44.

10:00 EST Resideo rises 15.0% - Resideo is up 15.0%, or $2.56 to $19.64.

10:00 EST MGM Resorts falls -7.6% - MGM Resorts is down -7.6%, or -$3.48 to $42.18.

09:50 EST Solowin Holdings Ltd trading resumes

09:47 EST DaVita rises 11.5% - DaVita is up 11.5%, or $13.04 to $126.64.

09:47 EST Generac falls -7.6% - Generac is down -7.6%, or -$9.44 to $114.35.

09:47 EST Sonic Automotive falls -9.5% - Sonic Automotive is down -9.5%, or -$5.45 to $52.00.

09:42 EST Beamr Imaging Ltd trading resumes

09:40 EST Byrna Technologies trading resumes

09:36 EST Lakeshore Acquisition II Corp trading halted, volatility trading pause

09:36 EST Foxo Technologies, M2i Global enter non-binding agreement for merger - FOXO Technologies (FOXO) has entered into a non-binding agreement ("Agreement") for a proposed merger with M2i Global (MTWO), which specializes in the development and execution of a complete global value supply chain for critical minerals for the U.S. government and U.S. free trade partners, as well as creating a strategic mineral reserve in partnership with the U.S. Federal Government. Minerals Metals Initiativ is a leader in engineering research and services, dedicated to ensuring the U.S. maintains a stable supply of critical materials for national defense and economic security. M2i aims to build a comprehensive global supply chain for critical minerals, in collaboration with the U.S. Federal Government and international partners, addressing the global shortage outside China and seizing the economic opportunity to meet increasing demand. M2i's mission is to unite expertise from government, industry, non-profits, and academia to secure guaranteed access to essential minerals and metals pivotal for national defense and economic security.

09:35 EST Byrna Technologies trading halted, volatility trading pause

09:34 EST Petros Pharmaceuticals enters AI-licensing agreement with software provider - Petros Pharmaceuticals announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as part of the Company's ongoing efforts to bring STENDRA over the counter. The technology will be integrated into the core tool the Company has already developed as part of its Self-Selection Study, which is currently underway.

09:27 EST Citizens Financial CSO Holly Ridgeway to retire, Brendan Goode to succeed - Citizens Financial announced that Brendan Goode will assume the role of chief security officer, effective April 29. Upon assuming the CSO role, Goode will report to Michael Ruttledge, CIO and Head of Enterprise Technology & Security. He will succeed Holly Ridgeway, who will retire from Citizens at the end of June.

09:25 EST AMTD IDEA Group announces $20M share repurchase program - AMTD IDEA Group announced that its board of directors has authorized a new share repurchase program under which the company may repurchase up to $20M of its American depositary shares or ordinary shares until the end of the last business day of the first quarter in 2024, U.S. Eastern Time.

09:17 EST Sono Group to file documentation to become fully reporting entity on OTCQB - The ordinary shares of Sono Group have been suspended from trading on Nasdaq since July 21, 2023. Following the recent announcement from The Nasdaq Stock Market that it will file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission to formally complete the delisting of the Company's ordinary shares, the Company is pleased to outline its strategic initiatives considering this development. As disclosed in the Company's Form 6-K submitted to the SEC on December 13, 2023, the Company received a decision of the Nasdaq Hearings Panel to delist the Company's ordinary shares from Nasdaq. The Panel's decision was received prior to the occurrence of certain significant corporate events: the insolvency plan of Sono Motors GmbH, the Company's sole subsidiary, becoming legally binding, the Company's decisive action to withdraw its application for preliminary self-administration proceedings, the closing of the investment from YA II PN, Ltd., and the subsequent funding of the first tranche of such investment. Having become current on its financial reporting with the SEC and having received an initial round of fresh funding, the Company intends to work towards meeting the initial listing requirements of The Nasdaq Capital Market. In the meantime, and in addition to these efforts, Sono Group N.V. is planning to apply for admission to trading on OTCQB. Such a listing would be aimed at generating additional liquidity for the Company's shares and facilitating investor activity as a fully reporting entity. The Company's leadership believes this step could potentially support and enhance shareholder value during this transition period.

09:13 EST Amdocs unveils CES24 suite - Amdocs will showcase its new CES24 suite, the most advanced version of the Amdocs Customer Experience Suite spanning BSS, OSS and network, at Mobile World Congress in Barcelona. CES24 utilizes the Amdocs amAIz generative AI platform to empower service providers to leverage telco-specific GenAI capabilities for any business and operational need, in a simple, trusted, secured and cost-effective manner. Key features of CES24 include its Customer Engagement Platform, an Amdocs-Microsoft complete telco-verticalized CRM solution serving both the consumer and enterprise markets. Alongside the CES Copilot's natural language processing, sentiment analysis, conversational AI and generative content creation capabilities, this CRM solution leverages the power of Microsoft Dynamics 365 and Azure to deliver a unified and omnichannel AI-driven customer journey.

09:09 EST Atara Biotherapeutics submits IND for ATA3219 to treat Lupus Nephriti - Atara Biotherapeutic announced its recent submission of an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus SLE with kidney involvement upus nephritis . "Despite therapeutic advances, there remains high unmet need in lupus nephritis, where standard of care and approved therapies have limited efficacy that often rely on multi-year, if not lifelong immune suppression," said Rajani Dinavahi, Chief Medical Officer at Atara. "We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference. We look forward to working with the FDA to initiate this study and advance ATA3219 into the clinic to potentially bring a new disease-modifying option for patients suffering from this chronic disease."

09:06 EST Immersion in licensing pact with Meta Platforms, no terms - Immersion (IMMR) announced that it has signed a license with Meta Platforms (META) to make Immersion's patents available to Meta and its affiliates' hardware, software, VR, and gaming products. "We are delighted to grant Meta Platforms, Inc. a license to our patents for haptic technologies. We are excited to license Meta Platforms, Inc. for their delivery of high-quality haptics in their devices," said Eric Singer, Immersion's President and CEO. Immersion's high-quality touch feedback technology enhances gaming peripherals and applications. Increasingly, haptics is being designed into VR gaming applications as more and more VR platforms and games incorporate high-quality tactile effects for more immersive operations

09:04 EST Ansys and Schaeffler extend agreement for additional three years - Ansys and Schaeffler announced they are extending their agreement for an additional three years. Schaeffler will rely on Ansys to standardize product development workflows, reduce waste from physical prototypes, and lower the company's overall carbon footprint through digital transformation. Schaeffler manufactures high-precision components and systems for drive train and chassis applications as well as rolling and plain bearing solutions for many industrial applications. Ansys and Ansys Apex Channel Partner CADFEM Germany GmbH will continue to provide customer support for Schaeffler as the company hones its digital engineering practices. The extension of the partnership will now see Ansys multiphysics solutions Ansys Mechanical, Ansys Fluent, Ansys Electronics, and Ansys Motor-CAD with enhanced computing capabilities through high-performance computing, applied across all divisions.

09:02 EST LiqTech and Razorback enter into a distribution agreement - LiqTech International and Razorback Direct Oilfield Solutions and Services have entered into a distribution agreement to commercialize LiqTech's produced water treatment filtration solution for re-injection and reuse, as well as lithium harvest, in five different states in the U.S. including Texas, Oklahoma, Louisiana, Ohio, and Pennsylvania. Leveraging LiqTech's proven ceramic silicon carbide filtration technologies, the Company's produced water treatment solution focuses on tertiary water treatment to facilitate re-injection and reuse and to meet current and future regulatory requirements. LiqTech's first commercial test unit for produced water deployed in May 2022 in the Middle East has successfully been operating for the past two years. The quality of the clean brine exceeds the performance requirements originally defined by the end user. Furthermore, the system operates with a low amount of chemicals while demonstrating excellent energy efficiency.

08:57 EST AIM ImmunoTech announces first subject dosed in Netherlands for Ampligen study - AIM ImmunoTech (AIM) announced the first subject has been dosed at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM's Ampligen with AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi for the treatment of late-stage pancreatic cancer. The DURIPANC Study is an investigator-initiated, exploratory, open-label, single-center study with the full name "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy." The primary objective of the Phase 1b portion is to determine the safety of combination therapy with Imfinzi and Ampligen. The primary objective of the Phase 2 portion is to determine the clinical benefit rate of the combination therapy. The study is expected to enroll up to 18 subjects in its Phase 1b portion and up to 25 subjects in its Phase 2 portion. Subjects will start with Ampligen 200 mg via IV infusion twice per week for a total of 6 weeks. Ampligen dose will be escalated to 400 mg according to a 3+3 DLT design. The first dose of Ampligen will be administered preferably 4-6 weeks after the last chemotherapy FOLFIRINOX dose. After two doses of Ampligen, the first dose of durvalumab 1500 mg via IV infusion will be introduced in week 2. Patients will continue to receive 1500 mg durvalumab via IV infusion every 4 weeks for up to a maximum of 48 weeks with the last administration on week 48 or until confirmed disease progression according to Response Evaluation Criteria in solid Tumors, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

08:53 EST CSP Inc. board raises quarterly dividend to 5c per share - The Company announced that the Board of Directors declared and raised the quarterly dividend to $0.05 per share payable March 08, 2024, to shareholders of record on the close of business on February 26, 2024.

08:52 EST Koppers Holdings increases quarterly dividend 17% to 7c per share - Koppers Holdings announced that its board of directors has approved a 17% increase in the planned quarterly dividend rate for 2024, from 6c to 7c per share of Koppers common stock. A quarterly dividend will be paid on March 25 to shareholders of record as of the close of trading on March 8.

08:49 EST Equus subsidiary provides update on reserves - Equus Total Return announced that its wholly-owned subsidiary Morgan E&P, has received from Cawley, Gillespie & Associates, an updated reserve estimate as of January 1, 2024. Morgan continues to acquire mineral rights in the Bakken/Three Forks formation in the Williston Basin of North Dakota, and on December 18, 2023, announced an increase in its acreage in this area from 4,747.52 net acres to 5,976.84 net acres, an increase of 1,229.32 net acres, or approximately 25.9%. Morgan engaged the petroleum engineering firm of CG&A to review and provide an updated reserve analysis of this asset using the December 29, 2023 NYMEX strip pricing. Using a discount rate of 10% the values of proved, probable, and possible reserves associated with the project are $31,986,856, $13,898,074, and $62,025,104, respectively. The most notable change in the reserve report is the conversion of possible reserves into proved developed producing reserves of $27,359,924, resulting from the successful completion of the two previously announced wells, the Baranko 1-28H and the Obrigewitch 1-33H. Morgan drilled both wells into their target zones of the Middle Bakken with the Baranko achieving a total depth of 19,920 feet and the Obrigewitch achieving a total depth of 21,356 feet. The wells were completed with 60-stage fracture stimulations. Both wells are currently in flowback. Using a discount rate of 10% the value of proved reserves increased 135% from the previously announced $13,575,442 million of proved undeveloped reserves to $31,986,856 million, of which $27,359,924 million is PDP and $4,626,930 million is PUD. CG&A continues to confirm forty-six gross drilling locations, in addition to the two wells already drilled. They have increased Morgan's net drilling locations from fifteen to eighteen. As additional net acreage and working interests are acquired, the resulting number of net drilling locations is expected to increase accordingly. Neither CG&A nor Morgan can guarantee any amounts that may be recoverable from these properties. Based on a historical analysis of the geologic strata that are the subject of Morgan's development rights CG&A has noted the estimated ultimate recovery from a single well is expected to be approximately 814,000 barrels of oil equivalent.

08:47 EST Silo Pharma says SP-26 ketamine implant demonstrates 'successful' drug delivery - Silo Pharma provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability. In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride in two loadings, 20% and 40%. Measurements and analysis demonstrated that the drug was successfully loaded into the engineered particles to encapsulate the implantable treatment. The structural stability and integrity of both the 20% and 40% loaded implants were maintained, with no leakage, degradation, or discoloration. "Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions," said Eric Weisblum, CEO of Silo. "We believe the initial testing provided sufficient validation of the delivery system for SP-26 and accordingly, our focus has shifted to testing of the ketamine formulation to measure drug dissolution and time-release action."

08:44 EST Blackstone announces growth investment in 7 Brew - Blackstone announced that Blackstone Growth and affiliated funds have made a growth equity investment in 7 Brew Coffee, which it calls "the next generation drive-thru beverage business." Blackstone's investment seeks to help enable 7 Brew to accelerate its already-rapid expansion across the U.S., in collaboration with its premier franchise partners, Blackstone added. Terms of the transaction were not disclosed. Todd Hirsch and Katie Storer of Blackstone said, "7 Brew's impressive growth to date is a testament to its strong team and franchisee partnerships. We are excited to partner with this business that is redefining the out-of-home coffee experience, by marrying a personal, human-centric customer service experience with premium products and exceptional efficiency."

08:37 EST Uber sees three-year cross bookings growth in mid to high teens CAGR - Uber's 3-year outlook also calls for adjusted EBITDA growth in a high 30% to 40% CAGR and free cash flow as a percentage of adjusted EBITDA of 90%+. Comments taken from investor presentation slides.

08:36 EST E2open announces appointment of Andrew Appel as CEO - E2open Parent Holdings announces the appointment of Andrew Appel as its new chief executive officer. Appel has served as e2open's interim CEO since October, bringing over 25 years of executive leadership experience, most recently as president and CEO of software and business intelligence leader IRI for nearly a decade.

08:32 EST Signing Day Sports appoints Borish to board of directors - Signing Day Sports announced the addition of Peter Borish to the Signing Day Sports board of directors. Peter Borish brings many years of experience. Since January 2015, he has held the positions of Chairman and Chief Executive Officer of Computer Trading Corporation.

08:31 EST Mobiquity Technologies partners with AWINR Brands - Mobiquity Technologies announces its partnership with AWINR Brands. This collaboration will leverage Mobiquity's new Conversion Platform, aimed at boosting both website traffic and sales conversion rates, and enhancing Return on Ad Spend, ROAS. Dean Julia, CEO of Mobiquity Technologies, stated, "We're confident in the partnership's ability to drive higher volumes of contextually relevant website traffic. This, in turn, will empower site owners to better utilize their first-party, opt-in data with the help of the platform's unique AI engine, enhancing their ability to identify and retarget a significantly larger segment of previously anonymous visitors, thereby improving sales conversions."

08:26 EST Gray Television brings Milwaukee Bucks games back to free OTA television - The Milwaukee Bucks are returning to broadcast television in Green Bay, Eau Claire-La Crosse, and Wausau, Wisconsin, on television stations owned by Gray Television, as part of the recently announced Bucks broadcast package from Weigel Broadcasting Co.'s WMLW The M in Milwaukee. Gray's stations will broadcast 10 Bucks games this season, beginning on Friday, February 23rd, when the Bucks play at the Minnesota Timberwolves. The games have been made available for local over-the-air distribution as part of the NBA's agreement with Diamond Sports Group, the owner of Bally Sports Wisconsin.

08:24 EST Provectus engages irlabs for investor relations services - Provectus Biopharmaceuticals announced that it has engaged IR Labs to develop a comprehensive investor relations and corporate communications program for the Company. Ed Pershing, Chairman of Provectus's Board of Directors said, "We are pleased to have irlabs and Alyssa Barry join our team as we seek to increase Provectus's investor communication and engagement and expand the Company's visibility and outreach to the investment community."

08:23 EST ProPhase Labs announces preliminary results for dietary supplement Equivir - ProPhase Labs announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which - if confirmed at the end of the clinical trial program - may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19. Overall, in the initial 150 patient group there were approximately 46 incidences of upper respiratory viral infections. 62.3% of the patients in the placebo group acquired a viral infection versus only 37.7% in the Equivir group. Additional key statistics from the initial findings are: 39% of the placebo population acquired an upper respiratory viral infection vs 22.9% in the Equivir group. After 4 days of illness, only 3% of the Equivir group still had mild symptoms vs 55% in the placebo group. The average severity was 16% less severe when taking Equivir vs the placebo. No patients in the Equivir group became ill a second time while 2 patients in the placebo group had a second upper respiratory viral infection.

08:21 EST Microchip announces TimeProvider 4500 Grandmaster - The operators of critical infrastructure market segments such as 5G telecommunications, power utilities and transportation need to continuously upgrade their networks with technology capable of delivering higher processing speeds and highly accurate time sources that are not dependent on the Global Navigation Satellite System constellations like GPS, GALILEO and QZSS. To provide network operators a terrestrial alternative for distributing very accurate time, Microchip Technology announces the new TimeProvider 4500 grandmaster, a hardware timekeeping platform that provides high-speed network interfaces up to 25 Gbps and enables precise time accuracy of less than one nanosecond. The TimeProvider 4500 grandmaster is capable of supporting very-high-capacity Precision Time Protocol transactions. The innovative hardware platform enables higher IEEE-1588 scalability for thousands of clients. In network locations where range and capacity need to be balanced, namely in C-band 5G deployments, it is critical to be able to serve thousands of gNodeB from a single grandmaster. Depending on the specific sites, the grandmaster could serve very few or a large number of gNodeB base stations. This results in cost-effective and flexible deployments for operators regardless of scale.

08:18 EST Tilray's 10 Barrel Brewing launches Pub Ice - 10 Barrel Brewing, a subsidiary of Tilray Brands, announces the release of its newest beverage, Pub Ice. "We're thrilled to introduce Pub Ice to the world," said Brian Hughes, Marketing Director at 10 Barrel Brewing. "It's a drink that embodies the 'Cheap Fun' culture so many fans know and love, appreciable both as a delicious, thirst-quenching refreshment, and as a reminder to not take ourselves too seriously. It's the perfect drink to add even more fun to any gathering or celebration."

08:16 EST Provident Bank appoints Tom Mathew as First VP, Deputy Compliance Officer - Provident Bank recently welcomed Tom Mathew as First Vice President, Deputy Compliance Officer. In addition, Mr. Mathew serves as Deputy Compliance Officer for Provident's insurance subsidiary, Provident Protection Plus, and as Chief Compliance Officer for Beacon Trust, Provident's wealth management subsidiary. Mr. Mathew is responsible for managing compliance and regulatory requirements for these respective business lines within the organization. In addition, he evaluates compliance risk to develop risk-based compliance testing of existing procedures and controls to identify, detect, and correct non-compliance. He also partners with senior management in developing and communicating training initiatives to inform staff and stakeholders about compliance requirements. Most recently, he was Vice President, Director of Compliance with HSBC Bank.

08:14 EST Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO - Ocuphire Pharma announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, CSDO, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, CFO, effective today. Prior to joining Ocuphire, Jayagopal served as the Chief Scientific Officer of Opus Genetics. Before joining Ocuphire, Jhaveri served as Chief Financial Officer of Insilico Medicine.

08:11 EST MiNK Therapeutics announces first patient dosed in Phase 2 study for agenT-797 - MiNK Therapeutics announced the first patient dosed in a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center. The trial builds upon findings from MiNK's recently published clinical trial demonstrating that agenT-797 appears to overcome resistance to immune checkpoint inhibitors, with durable disease stabilization and a confirmed response in chemotherapy and anti-PD-1 refractory gastric cancer. "We are thrilled to collaborate with GI cancer expert Dr. Yelena Janjigian on this Phase 2 study, furthering the development of agenT-797 in refractory gastric cancer," stated Dr. Jennifer Buell, President and Chief Executive Officer at MiNK. "This study is designed to provide crucial insights into the clinical efficacy of agenT-797, while also assessing its potential synergies with chemotherapy and next-generation immune checkpoint inhibitors, botensilimab and balstilimab. This milestone underscores our unwavering commitment to advancing iNKT cell therapies to address the pressing unmet needs in cancer care and highlights the strength of our collaboration with Agenus to access these novel and exciting combinations to deliver meaningful benefits to our patients."

08:08 EST Great Lakes Dredge continues to see 'strong support' by Biden Administration - The company said, "We continue to see strong support from the Biden Administration and Congress for the dredging industry. In December 2022, the Omnibus Appropriations Bill for fiscal year 2023 was signed into law which included another record budget of $8.66 billion for the U.S. Army Corps of Engineers civil works program of which $2.32 billion is provided for the Harbor Maintenance Trust Fund to maintain and modernize our nation's waterways. In addition, the Disaster Relief Supplemental Appropriations Act for fiscal year 2023 was approved which included $1.48 billion for the Corps to make necessary repairs to infrastructure impacted by hurricanes and other natural disasters, and to initiate beach renourishment projects that will increase coastal resiliency. This increased budget and additional funding resulted in a strong bid market for 2023. For the twelve months ended December 31, 2023, the bid market, not including LNG or offshore wind projects, was $2.2 billion, up from $2.0 billion in 2022. Great Lakes won 33.7% of the 2023 bid market. The increase in the bid market was driven by a strong market for capital projects, which has already seen seven bids for port improvement projects including Freeport, San Juan, and Norfolk. The total capital bid market for port improvement projects through year end totaled $671.4 million, of which 36% was won by Great Lakes. We expect budgeted appropriations to support the funding of several previously delayed capital port improvement projects that are expected to bid in the first half of 2024, including Sabine, Houston, and Mobile. In addition, Great Lakes won two LNG projects totaling over $500 million."

08:08 EST Autonomix announced upcoming milestones - Expected Upcoming Milestones: Q1 CY2024: PoC human clinical trial site selection and agreements; Q1 CY2024: Principal Investigator selection and agreements; Q1 CY2024: Commence enrollment in PoC human clinical study evaluating proprietary ablation technology for treatment of pancreatic cancer pain; 2024: Complete ablation device design intended for clinical use; 2025: Complete development of ablation system and catheter in preparation for human pivotal trial; 2025: Launch combined sensing / ablation clinical trial; 2026: De novo submission; 2027: FDA clearance

08:06 EST S&W Seed names Vanessa Baughman as full-time CFO - The company's board of directors appointed Vanessa Baughman as the company's full-time CFO, effective February 12. Baughman has been serving as the company's Interim CFO and corporate Secretary since May 2023. Prior to joining S&W, Baughman served as CFO and Vice President of Finance of AgReliant Genetics, the third largest North American seed corn company, headquartered in Westfield, Indiana, from January 2019 to March 2023.

08:05 EST Erasca announces two CTCSAs with Novartis for trametinib - Erasca (ERAS) announced two clinical trial collaboration and supply agreements, CTCSAs, with Novartis (NVS) for the MEK inhibitor trametinib. The agreements will support the clinical development of the pan-RAF inhibitor naporafenib in combination with trametinib for the treatment of patients with RAS Q61X solid tumors in the Phase 1b SEACRAFT-1 trial and in patients with previously treated NRAS-mutant unresectable or metastatic melanoma in the randomized, pivotal Phase 3 SEACRAFT-2 trial. Erasca is sponsoring the trials, and Novartis is supplying trametinib at no cost. "We are excited to work with Novartis to further evaluate the promising clinical development of naporafenib in combination with trametinib in our SEACRAFT trials as part of our two lead indications: NRASm melanoma and RAS Q61X solid tumors," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "Both trials are supported by compelling anti-tumor activity with a tolerable and manageable adverse event profile demonstrated in clinical data generated by Novartis. We expect to initiate our SEACRAFT-2 Phase 3 trial in the first half of 2024 and report initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors between the second and fourth quarters of 2024."

08:03 EST Citius announces resubmission of BLA to FDA forLYMPHIR - Citius Pharmaceuticals announced the resubmission of the Company's Biologics License Application, or BLA, FDA for LYMPHIR, or denileukin diftitox, an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma, or CTCL, after at least one prior systemic therapy. The resubmission follows ongoing engagement with the FDA resulting from a Complete Response Letter received on July 28, 2023. Citius believes it has addressed enhanced product testing and additional manufacturing controls noted in the letter. There were no safety or efficacy issues cited and no additional trials required. Based on Center for Drug Evaluation and Research timelines, FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act date is expected within 30 days of resubmission.

08:03 EST Georgia Power announces Vogtle Unit 4 reaches initial criticality - Georgia Power announced today that Unit 4 at the Vogtle nuclear expansion project near Waynesboro, Georgia, has safely reached initial criticality. Initial criticality is a key step during the startup testing sequence and demonstrates that -- for the first time -- operators have safely started the nuclear reaction inside the second reactor. This means atoms are being split and nuclear heat is being made, which will be used to produce steam. Now that the Unit 4 reactor has reached criticality, operators will continue to raise power to support synchronizing the generator to the electric grid and begin producing electricity. Then, operators will continue increasing power through multiple steps, ultimately raising power to 100%. Georgia Power is the largest electric subsidiary of Southern Company.

07:56 EST ZyVersa Therapeutics highlights publication on inflammasome activation - ZyVersa Therapeutics highlights data from a review article published in Nature Reviews Neurology. This article provides increasing evidence that activation of several types of inflammasomes and extracellular ASC specks contribute to the development and progression of multiple neurological diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, traumatic brain injury, and stroke. In the paper titled, "Inflammasomes in neurological disorders - mechanisms and therapeutic potential," the authors reviewed 297 published papers that included data from cell cultures, preclinical disease models, and human tissue analysis to summarize the current evidence for and understanding of inflammasome activation in various neurological diseases. Key learnings include: Many neurological conditions involve an underlying chronic inflammasome-mediated inflammatory process that worsens the trajectory of these conditions. Beyond NLRP3, evidence suggests that other inflammasomes, including but not restricted to NLRP1, NLRC4, and AIM2, and their downstream effectors contribute to neuropathology in AD, PD, ALS, MS, stroke, epilepsy, and TBI. Inflammasome-induced release of ASC specks into the extracellular space seems to be important in the speed of neurodegeneration in conditions such as AD and PD. The authors concluded, "Use of inflammasome-targeted therapeutic approaches could improve existing therapeutic strategies for multiple neurological conditions.

07:45 EST Uber jumps 6% to $73.30 in premarket after announcing $7B share buyback

07:37 EST Medicenna Therapeutics sees cash runway into 2Q25 - As of December 31, 2023, cash and cash equivalents were $21.8 million, compared to $25.7 million on September 30, 2023.

07:32 EST SolarEdge receives UL1741-SB certification for SolarEdge 330kW Inverter - SolarEdge announced that its new high-power DC-optimized SolarEdge 330kW Inverter system for community and ground mount solar has received UL1741-SB certification and is now deployed with its first customer in the U.S.

07:32 EST Inspira receives patent for orbiting blood oxygenation delivery system - Inspira Technologies OXY has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA ART500 device. This innovation has 16 claims found to be novel. The orbiting blood oxygenation delivery system, or VORTX, is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape. The current fiber technologies used for blood oxygenation cause substantial damage to the patient's blood cells. Unlike the natural laminar blood flow in blood vessels inside the body, in existing fiber oxygenators, the blood is "forced" to flow in a harmful turbulent flow through many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant resistor to blood flow, high-pressure differences are formed and cause significant damage to the various blood components, including, high hemolysis, damage to white blood cells, activation of the inflammatory system in the body, activation of the immune system, and blood clotting.

07:27 EST GameSquare announces special meeting of stockholders to vote on FaZe merger - GameSquare Holdings (GAME) announced the Company is holding a special meeting of stockholders on February 27, 2024, at 10:00 a.m. ET to vote on the previously announced merger with FaZe Holdings Inc. (FAZE). GameSquare's shareholders of record as of the close of business on January 5, 2024, may attend the Special Meeting, which will be held at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto, Ontario M5L 1A9.

07:26 EST Microbix expects to generate 'meaningful' net earnings growth across 2024 - Microbix will continue to drive sales growth across all of its business lines, and work to keep improving percentage gross margins and driving bottom-line results. Management currently expects Microbix to generate meaningful year-over-year growth in revenues and net earnings across full-year fiscal 2024.

07:25 EST Benson Hill names Susan Keefe as CFO, effective March 29 - Benson Hil announced that Susan Keefe has been appointed Chief Financial Officer, effective March 29 .Keefe succeeds Dean Freeman, who is leaving the company to pursue other opportunities. Freeman will continue to serve in the role through March 29 to ensure a smooth transition of responsibilities.

07:23 EST VBI Vaccines gets $2.5M upfront in deal with Brii Bio for assets and licensing - VBI Vaccines announced agreements whereby Brii Biosciences subject to certain activities, is expected to: acquire the intellectual property for VBI-2601, VBI's HBV immunotherapeutic development program, and eliminate payment obligations from the July 2023 agreements between VBI and Brii Bio, acquire manufacturing capabilities and certain related assets at VBI's Rehovot, Israel manufacturing facility, and enter into an exclusive license to develop and commercialize VBI-1901, VBI's glioblastoma GBM immunotherapeutic candidate, in the Asia Pacific region APAC , excluding Japan. Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio. VBI received $2.5M of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5M of consideration, subject to achievement of certain activities, with a target completion date of June 30 . The proceeds from these agreements will be used for reduction of debt under the Company's current facility with K2 HealthVentures.

07:16 EST Ball Corp. says regulatory review process for sale to BAE Systems complete - Ball Corporation (BALL) announced that the U.S. Department of Justice has ended its review, and allowed its review period to expire, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the announced sale of Ball's aerospace business to BAE Systems (BAESY) for approximately $5.6B in cash proceeds. With the earlier receipt of other regulatory approvals and clearances for closing this transaction, including the Defense Counterintelligence and Security Agency and the Committee on Foreign Investments in the United States, the parties expect to close the transaction in the near term, subject to the satisfaction or waiver of the remaining customary closing conditions.

07:13 EST Plug Power announces expense reduction plan to save over $75M annually - In a strategic move to enhance its financial performance and ensure long-term value creation in a competitive market, Plug Power announced a comprehensive initiative designed to significantly reduce its annual operational expenses by more than $75 million. This ambitious plan will be executed with an expected one-time implementation cost of $15 million. The initiative encompasses a broad range of measures, including operational consolidation, strategic workforce adjustments, and various other cost-saving actions. These measures are aimed at increasing efficiency, improving scalability, and maintaining Plug's leadership position in the renewable energy industry. Operational Consolidation: A key element of this initiative is the consolidation of operations, intended to optimize the allocation of resources and streamline processes. This consolidation effort will enable Plug to achieve economies of scale, eliminate redundancies, and enhance productivity across its global operations. Strategic Workforce Adjustments: As part of its commitment to maintaining a dynamic and efficient workforce, Plug will undertake strategic adjustments to its staffing levels. This decision is made in the interest of preserving the Company's agility and innovation capacity. Affected employees will be supported with comprehensive severance packages and resources for career transition. Additional Cost-Saving Measures: In addition to operational and workforce adjustment strategies, Plug will implement a series of additional measures to further reduce expenses. These will include optimizing supply chain management, curtailing discretionary spending, and leveraging automation and digital technologies to enhance operational efficiency. Plug's leadership, including CEO Andy Marsh, reaffirms the Company's dedication to implementing these changes with the highest regard for all stakeholders, including investors, employees, customers, and partners. With this initiative, Plug reinforces its commitment to driving the global transition to renewable energy. The expense reduction plan is a critical step in ensuring the Company's resilience and adaptability in navigating the evolving energy landscape.

07:11 EST Veeva selected by Boehringer Ingelheim - Veeva Systems announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives. Boehringer Ingelheim will use Veeva Vault CTMS in its animal health business unit to manage and monitor trials and Veeva Vault eTMF for real-time inspection readiness, visibility, and control. The company will also use Vault RIM applications, including Veeva Vault Registrations, Veeva Vault Submissions, and Veeva Vault Submissions Archive for advanced regulatory processes. Connecting these applications on a single cloud platform will enable real-time access to data and seamless information exchange.

07:11 EST BAE Systems secures regulatory approvals for acquisition of Ball Aerospace - BAE Systems has now received necessary regulatory approvals to successfully complete the acquisition of Ball Aerospace, which will add market-leading space and defense capabilities to the company's portfolio of products and services. In the coming days, BAE Systems and Ball Corporation will be executing the steps needed to complete the transaction and close on the Ball Aerospace acquisition.

07:09 EST Brunswick's Fliteboard introduces Flite AIR, Flite AIR PRO - Fliteboard, a brand of Brunswick Corporation, announced the introduction of Flite AIR and Flite AIR PRO, the most attainable models in the brand's portfolio and a significant milestone for Flite as it continues to appeal to a broader consumer at different price points. "We are thrilled to announce the launch of Flite AIR and Flite AIR PRO today at the Miami International Boat Show, one of the most important shows in the world and a wonderful opportunity to showcase these transformational products to a global audience," said, David Trewern, Fliteboard Founder, CEO and Product Architect. "Flite AIR is great for using on and off boats, docks, rocky beaches, or for school and rental applications. Compatible with most Flite products, the boards can even be used by pros as a durable and lightweight alternative to our carbon fiber boards."

07:09 EST TScan to host virtual KOL event to discuss Phase 1 heme malignancies study - TScan Therapeutics announced the Company will host a virtual key opinion leader, KOL, event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research. The event will provide an in-depth review of the oral presentation related to TScan's ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation in patients with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphocytic leukemia.

07:06 EST Greenland Technologies approves spin-off of its drivetrain systems business - Greenland Technologies Holding announced that the Company's Board of Directors had approved a spin-off of its drivetrain systems business, and approved a plan to separate its electric industrial vehicles and drivetrain systems segments into two independent, publicly-traded companies. The Company expects to create these companies through a tax-free spin-off of its drivetrain systems segment to the Greenland shareholders. There are no guarantees the contemplated spin-off will occur or that it will occur on the anticipated timeline given economic conditions and changes in the financial markets. After the proposed spin-off, Greenland will be solely comprised of the Company's current industrial electric vehicle business under its HEVI brand. Under the Board-approved strategic plan, Greenland's existing drivetrain systems for material handling machineries and vehicles would operate post-spin-off as a separate, independently managed and publicly traded company on the OTC market. Current Greenland shareholders will continue to own and trade shares with no change. They will also receive a to be determined allocation of shares in the new spin-off company comprised of the non-industrial EV operations.

07:05 EST Shineco announces 1-for-10 reverse stock split - Shineco announced that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share, at a ratio of 1-for-10. The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The reverse stock split is expected to become effective on February 16, 2024, and the shares are expected to begin trading on the split-adjusted basis on the Nasdaq Stock Exchange under the Company's existing trading symbol "SISI" at the market open on February 16, 2024. The new CUSIP number for the Company's common stock will be 824567408.

06:56 EST Uber announces inaugural $7B share repurchase authorization - Uber Technologies announced that its Board of Directors has authorized the repurchase of up to $7B of the company's common stock. "Today's authorization of our first-ever share repurchase program is a vote of confidence in the company's strong financial momentum. We will be thoughtful as it relates to the pace of our buyback, beginning with actions that partially offset stock-based compensation, and working towards a consistent reduction in share count," said Prashanth Mahendra-Rajah, CFO.

06:51 EST Royal Gold announces execution of additional agreement with Centerra Gold - Royal Gold (RGLD) announced that its wholly owned subsidiary, RGLD Gold AG, has executed an additional agreement with Centerra Gold (CGAU) and its wholly-owned subsidiary, Thompson Creek Metals Company, with respect to the Mount Milligan Mine that provides near-term cash and gold consideration to Royal Gold in return for long-term cost support that will allow an extension of the mine life of Mount Milligan to 2035 and the potential for a future increase in mine life beyond 2035. Royal Gold holds a stream interest at the Mount Milligan Mine comprising a gold stream that provides for delivery of 35% of the payable gold in return for a cash payment of $435 per ounce, and a copper stream that provides for delivery of 18.75% of the payable copper in return for a cash payment of 15% of the spot copper price. The Existing Stream Agreement remains in place and is unaffected by these additional agreements. Significant consideration payable to Royal Gold including cash and gold in the near term, and a free cash flow interest in the long term. Royal Gold will receive approximately $125M in near-term consideration, comprised of $24.5M of cash and 50,000 ounces of gold, and a long-term free cash flow interest on the Mount Milligan Mine. Long-term cost support to the Mount Milligan Mine to allow for an extended mine life. Royal Gold will provide cost support payments for metal deliveries starting in approximately 2030 that provide a basis for an immediate reserve increase and extension of the Mount Milligan mine life to 2035.

06:49 EST BWX Technologies unit awarded $122M contract extension from TVA - BWX Technologies announced that its Nuclear Fuel Services subsidiary was awarded a $122M contract extension from the Tennessee Valley Authority for the downblending of highly enriched uranium into low enriched uranium. Under this contract, NFS will continue to provide downblending services to the TVA in support of the National Nuclear Security Administration's defense programs objectives. This contract extension continues the current downblending operations from July 2025 to June 2027.

06:43 EST Griid Infrastructure to double capacity of Lenoir City bitcoin mining operations - Griid Infrastructure announced plans to double the capacity of its bitcoin mining operations in Lenoir City, Tenn. from 20 MW to 40 MW in mid-2024 by adding a new site expected to power approximately 6,500 machines. "We're focused on building our growth and expanding our capacity by moving sites like this from our power pipeline to production," said Trey Kelly, CEO of Griid. "We're especially pleased to be expanding our footprint in the Tennessee Valley, where the Tennessee Valley Authority's mix of affordable, reliable and low-carbon electricity has made this area an excellent long-term location to mine bitcoin."

06:38 EST Clean Energy announces completion of RNG facility in Marshall County - Clean Energy Fuels announced the completion of its latest renewable natural gas, or RNG, facility in Marshall County, Iowa. The Marshall Ridge Dairy project is expected to produce 1.7 million gallons of low carbon-intensity RNG annually. The three-digester facility located in State Center, Iowa, is now producing pipeline quality RNG and injecting it into the national grid. RNG is a sustainable fuel derived from organic waste that provides an immediate and significant carbon reduction in transportation. Financed through one of Clean Energy's production joint ventures and developed by Dynamic Renewables, the project totaled $42M. Methane from the approximately 240,000 gallons of manure produced by the 8,000-cow herd each day will be converted into biogas and ready-to-use clean fuel for heavy-duty fleets across the country. Clean Energy is in process of filing the necessary applications to generate federal and state environmental credits.

06:29 EST Taylor Morrison sees FY24 home closings 12,000 - Sees FY24 average closing price $600,000. Sees FY24 home closings gross margin 23%-23.5%. Sees FY24 ending active community count 320-325. Sees FY24 effective tax rate 25%. Sees FY24 land and development spend $2.3B-$2.5B.

06:24 EST Greenwich LifeSciences provides update on Phase III clinical trial Flamingo-01 - Greenwich LifeSciences provided the following update on the Phase III clinical trial, Flamingo-01. The Flamingo-01 DSMB met twice in 2023 and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date. Approximately 30 clinical sites with 87 locations at multiple hospitals and the largest oncology network in the US are currently recruiting patients. Pending European regulatory approval, which is expected in 2024, contracts are in place to add up to an additional 105-120 sites in Europe. European academic networks in each country are planning to participate in Flamingo-01. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in the third arm. For the HLA-A*02 randomized arms, the trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. CEO Snehal Patel commented, "With the addition of the European sites and approximately 150 total sites, peak enrollment rates could be reached by the end of 2024 allowing for a refinement in the interim analysis. Currently, enrollment will likely end before the interim analysis is triggered by 14 events. However, the interim analysis could be modified such that an additional sizing interim analysis is conducted before enrollment ends to reaffirm the size of the 2 randomized arms. While the hazard ratio of 0.3 assumes that the recurrence rate of the treated arm will be 30% of the recurrence rate in the placebo arm and thus a 70% reduction in recurrence rate, and while the Phase II trial showed even greater reduction in recurrence rate, we are likely to see recurrences in the treated arm of the Phase III trial and have designed the trial accordingly. Using the early Phase III trial data to reaffirm the size of the arms of the Phase III trial may be the best information we could use to reduce risk and improve the chances of success of Flamingo-01."

06:18 EST Centerra Gold reports 2023 year-end gold mineral reserves 3.6M ounces - Centerra Gold announces its 2023 year-end estimates for mineral reserves and mineral resources. Proven and probable gold mineral reserves were 3.6M ounces and proven and probable copper mineral reserves were 961 million pounds, as of December 31, 2023. Measured and indicated gold mineral resources were 6.9 million ounces as of December 31, 2023, driven by a significant increase at Mount Milligan. The Company is encouraged by the large mineral endowment at Mount Milligan setting the stage for potential future mine life growth.

06:14 EST Adagio Medical to be public through Arya Sciences Acquisition Corp combination - Adagio Medical and ARYA Sciences Acquisition Corp IV (ARYD) announced they have entered a definitive agreement for a business combination. Upon closing of the transaction, Adagio Medical will become a subsidiary of Aja Holdco, which will operate with the existing Adagio Medical management team under the name "Adagio Medical". The combined company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol (ADGM). Investors have committed to participate in the transaction in the form of $20M in convertible debt and $22M in equity financing. Investors in the financing include affiliates of Perceptive Advisors, RA Capital Management, RTW Investments and ATW Partners. The transaction implies a post-transaction fully diluted equity value of the combined company of $128M and a fully diluted enterprise value of $113M, as further described in the investor presentation. Current Adagio Medical shareholders and holders of certain vested equity awards are converting 100% of their existing equity interests into shares or equivalent awards of the combined company. Non-redeeming holders of ordinary shares of Arya will be converting their ordinary shares into common stock of the combined company on a one for one basis. Subject to the assumptions described in the Investor Presentation, at closing, current investors in Adagio Medical (excluding Perceptive Advisors and RA Capital) are expected to own approximately 10.2% and Perceptive and ARYA Sciences Holdings IV, an affiliate of Perceptive Advisors and sponsor of ARYA, collectively, are expected to hold approximately 58.2% of the Combined Company. The respective boards of directors of both ARYA and Adagio Medical have approved the proposed transaction. Completion of the transaction, which is expected in the second quarter of 2024, is subject to approval of ARYA's and Adagio Medical's shareholders and the satisfaction of certain other customary closing conditions.

06:10 EST Acri Capital Acquisition extends deadline for initial business combination - Acri Capital Acquisition announced that, in order to extend the date by which the company must complete its initial business combination from February 14, 2024 to March 14, 2024, Acri Capital Sponsor LLC, the sponsor of the company, has deposited into its trust account an aggregate of $75,000. Pursuant to the company's Amended and Restated Certificate of Incorporate currently in effect, the company may extend on monthly basis from July 14, 2023 until April 14, 2024, or such an earlier date as may be determined by its board to complete a business combination by depositing the New Monthly Extension Payment for each month into the Trust Account.

06:08 EST Carvana expands same day vehicle delivery to Philadelphia area - Carvana announced its expansion of same day vehicle delivery to the Philadelphia area. Now select Philadelphia area residents can take delivery of their vehicle within hours of placing an order on Carvana.com. Select customers interested in selling their current vehicles to Carvana can also benefit from same day drop-off at specific locations throughout the state.

06:05 EST Generac sees FY24 net sales up 3%-7% from last year - The Company is initiating guidance for FY24 that anticipates a return to net sales growth as compared to the prior year. This growth is expected to be driven primarily by residential product sales growth in the mid-teens range, led by shipments of home standby generators and residential energy technology products. Partially offsetting this projected strength, C&I product sales are expected to decline at a rate of approximately 10%, primarily due to weakness with certain direct telecom, rental, and "beyond standby" customers. As a result of these factors, full-year net sales are expected to increase between 3%-7% as compared to the prior year, which includes a slight favorable impact from foreign currency. Additionally, the Company expects net income margin, before deducting for non-controlling interests, to be approximately 6.5%-7.5% for the FY24. The corresponding adjusted EBITDA margin is expected to be approximately 16.5%-17.5%. The Company expects to maintain strong levels of operating and free cash flow generation for the full year, with free cash flow conversion from adjusted net income expected to be approximately 100%. Aaron Jagdfeld, CEO, concluded, "In 2024, we expect to return to consolidated sales growth and year-over-year margin expansion for the full year period while also continuing to invest for future growth. Importantly, the mega-trends that support these expectations as well as our robust long-term growth outlook remain firmly intact. As reliance on electricity continues to increase and supply-demand imbalances remain a challenge for grid operators, we will continue to execute our strategic plan to lead the evolution to more resilient, efficient, and sustainable energy solutions."

06:01 EST Barrick Gold announces new $1B share repurchase program - Barrick Gold announced that it plans to undertake a new share repurchase program for the buyback of its common shares. Barrick's board of directors has authorized a new program for the repurchase of up to $1B of the company's outstanding common shares over the next 12 months at prevailing market prices in accordance with applicable law. In connection with the new share repurchase program, Barrick has terminated the share repurchase program announced by the company on February 15, 2023. The company did not repurchase any common shares under its 2023 share repurchase program. Barrick repurchased $424M in common shares under its 2022 share repurchase program.

05:42 EST Motorola Solutions acquires Silent Sentinel, terms undisclosed - Motorola Solutions has acquired Silent Sentinel, a provider of specialized, long-range cameras based in Ware, United Kingdom. Terms of the transaction were not disclosed.

05:35 EST Invitae files for Chapter 11 protection, pursues sale process - Invitae announced that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the company intends to safeguard its business, customers, patients and employees while working to execute an efficient and value-maximizing sale process with the support of its senior noteholders. To ensure the business will operate in the ordinary course during chapter 11, Invitae has sought court approval to fund the case using its cash on hand. The company intends to transition into chapter 11 without disrupting operations, and is committed to serving its customers and patients and meeting go-forward commitments to employees and vendors. Invitae files for chapter 11 with the support of its senior secured noteholders as agreed to in a transaction support agreement. The TSA includes a commitment from the senior secured noteholders to provide an affirmative vote in support of the company's chapter 11 plan, support the company's sale process, and agree to the consensual use of the company's cash on hand during the cases.

05:24 EST MW Storage selects Fluence Energy to deliver joint project in Germany - MW Storage has selected Fluence Energy GmbH, a subsidiary of Fluence Energy, to deliver one of the largest battery-based energy storage projects in continental Europe. The 100 MW/ 200 MWh storage system will be located in Arzberg, Wunsiedel district, near the German - Czech border. The project underlines the long-standing partnership between Fluence and MW Storage that previously has delivered projects in Finland and Switzerland. The German Federal Network Agency estimates the demand for large-scale battery storage will reach 23.7GW in 2037, which corresponds to 237 projects of the same size as the one to be delivered by MW Storage and Fluence.

05:13 EST CGI Inc., LocalTapiola extend C$284M strategic partnership for five years - CGI and LocalTapiola have extended their long-term strategic partnership for an additional five years as LocalTapiola advances its comprehensive business transformation program. Under the new contract, valued at C$284M, CGI will apply new technologies to help LocalTapiola generate cost savings and drive operational efficiency. CGI also will continue to provide development and maintenance services for the majority of information systems within LocalTapiola's insurance business.